Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 855

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 855
---
 Inc.” from “Iris Acquisition Corp.”FOR☐AGAINST☐ABSTAIN☐(5B)Advisory Charter Proposal 5B — To authorize the issuance of up to 500,000,000 shares of common stock, and up to 1,000,000 shares of “blank check” preferred stock, the rights, preferences and privileges of which may be designated from time to time by ParentCo’s board of directors.FOR☐AGAINST☐ABSTAIN☐(5C)Advisory Charter Proposal 5C — To provide that the removal of any director be only for cause and by the affirmative vote of at least 66 2∕3% of ParentCo’s then-outstanding shares of capital stock entitled to vote generally in the election of directors.FOR☐AGAINST☐ABSTAIN☐(5D)Advisory Charter Proposal 5D — To make ParentCo’s corporate existence perpetual as opposed to Iris’s corporate existence, which is required to be dissolved and liquidated 36 months following the closing of its initial public offering if it does not complete a business combination in that time, and to remove from the proposed ParentCoFOR☐AGAINST☐ABSTAIN☐ 23-14369-11 C2.1 P55

TABLE OF CONTENTS

3Certificate of Incorporation the various provisions applicable only to special purpose acquisition corporations.(5E)Advisory Charter Proposal 5E — To provide that ParentCo will not be subject to Section 203 of the DGCL.FOR☐AGAINST☐ABSTAIN☐(5F)Advisory Charter Proposal 5F — To increase the required vote thresholds for approving amendments to the proposed ParentCo Certificate of Incorporation and bylaws to 66 2∕3%.FOR☐AGAINST☐ABSTAIN☐(6)The Election of Directors Proposal — If the Business Combination Proposal and ParentCo Charter Proposal are approved, to elect, on an advisory and non-binding basis, the following three directors to serve on the board of directors of the post-business combination company: Nicholas Fernandez and Ji Yeon Baek, as Class I directors, until the 2025 annual meeting of stockholders, Eun Sook Lee, as a Class II director, until the 2026 annual meeting of stockholders, and Chris Kim, as a Class III director, until the 2027 annual meeting of stockholders,